Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$795
in 4 filings, $795 under 10b5-1 plans

Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-15 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion 10b5-1 +10,625 124,516
2024-02-15 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion · Restricted Stock Units 10b5-1 −10,625 31,875
2024-02-15 Shaff Eric D. CEO and President Exercise or conversion 10b5-1 +31,250 146,870
2024-02-15 Shaff Eric D. CEO and President Exercise or conversion · Restricted Stock Units 10b5-1 −31,250 93,750
2024-02-15 Henn Matthew R. Exercise or conversion 10b5-1 +11,250 67,606
2024-02-15 Henn Matthew R. Exercise or conversion · Restricted Stock Units 10b5-1 −11,250 33,750
2024-02-15 Young Teresa L. Exercise or conversion 10b5-1 +10,625 19,079
2024-02-15 Young Teresa L. Exercise or conversion · Restricted Stock Units 10b5-1 −10,625 31,875
2024-02-15 von Moltke Lisa Exercise or conversion 10b5-1 +11,875 21,388
2024-02-15 von Moltke Lisa Exercise or conversion · Restricted Stock Units 10b5-1 −11,875 35,625
2024-02-15 Ege David S. Exercise or conversion 10b5-1 +11,875 78,866
2024-02-15 Ege David S. Exercise or conversion · Restricted Stock Units 10b5-1 −11,875 35,625
2024-02-15 Arkowitz David Chief Financial Officer Exercise or conversion 10b5-1 +10,625 186,381
2024-02-15 Arkowitz David Chief Financial Officer Exercise or conversion · Restricted Stock Units 10b5-1 −10,625 31,875
2024-02-14 DesRosier Thomas Chief Legal Officer and EVP Grant or award · Stock Option (Right to Buy) 10b5-1 +213,750 213,750
2024-02-14 DesRosier Thomas Chief Legal Officer and EVP Grant or award · Stock Option (Right to Buy) 10b5-1 +287,905 287,905
2024-02-14 DesRosier Thomas Chief Legal Officer and EVP Grant or award · Restricted Stock Units 10b5-1 +35,625 35,625
2024-02-14 Shaff Eric D. CEO and President Grant or award · Stock Option (Right to Buy) 10b5-1 +637,500 637,500
2024-02-14 Shaff Eric D. CEO and President Grant or award · Stock Option (Right to Buy) 10b5-1 +822,580 822,580
2024-02-14 Shaff Eric D. CEO and President Grant or award · Restricted Stock Units 10b5-1 +106,250 106,250

Page 15 of 23 · 458 trades